{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Inhibikase Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"IKT"},"Address":{"label":"Address","value":"3350 RIVERWOOD PARKWAY SE,SUITE 1900, ATLANTA, Georgia, 30339, United States"},"Phone":{"label":"Phone","value":"+1 678 392-3419"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.inhibikase.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"C. Warren Olanow","title":"Chief Medical Officer"},{"name":"Milton H. Werner","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}